Research peptide writing from the inside.

Industry reality

How to choose a legit UK research peptide supplier: a 2026 checklist

By the Lab77 Peptides team · 30 September 2026 · ~9 min read

Seven checks every researcher should run before ordering: own-name COAs, HPLC chromatograms, Janoshik portal verification, UK stock confirmation, company identity, payment options, and price sanity. With Lab77’s own score against the checklist.

Industry reality

How to spot a fake research peptide supplier (UK 2026)

29 April 2026 · ~9 min read

A 12-point checklist for vetting any UK research-peptide supplier, written by a UK supplier. Includes us scoring ourselves transparently against the same criteria.

Lab literacy

How to read a Janoshik HPLC report: line by line

By the Lab77 Peptides team · 29 April 2026 · ~7 min read

An annotated walkthrough of a real Janoshik Certificate of Analysis. What every line means, how to verify the batch independently, and how to spot a fake report.

Lab literacy

Bacteriostatic water vs sterile water for peptide reconstitution

By the Lab77 Peptides team · 30 September 2026 · ~7 min read

The difference between bacteriostatic water and sterile water for injection, when to use each, why benzyl alcohol extends multi-use vial stability to 28 days, step-by-step reconstitution protocol, special cases by peptide type, and UK sourcing guide.

Compound deep-dive

TB-500: the Thymosin Beta-4 fragment

By the Lab77 Peptides team · 12 May 2026 · ~10 min read

A synthetic peptide built around the conserved LKKTET actin-binding motif of Thymosin Beta-4. Forty years of Goldstein and Kleinman literature. And the fragment-versus-full-protein chemistry question that most suppliers leave fuzzy.

Compound deep-dive

Semaglutide: the GLP-1 receptor agonist that defined the modern era

By the Lab77 Peptides team · 10 May 2026 · ~10 min read

A 31-amino-acid molecule from Novo Nordisk. Three small modifications to native GLP-1 produced an 11000-fold half-life jump. STEP-1 (14.9 percent body-weight reduction at 68 weeks) and SELECT (20 percent MACE reduction in non-diabetic CVD adults). The benchmark every later compound is measured against.

Compound deep-dive

Retatrutide: the triple-receptor agonist

By the Lab77 Peptides team · 6 May 2026 · ~10 min read

A 39-amino-acid synthetic peptide developed by Eli Lilly that activates three receptors at once: GIP, GLP-1, and glucagon. The first trinity agonist to publish a full Phase 2 dataset (Jastreboff NEJM 2023). 24.2 percent body-weight reduction at 48 weeks. TRIUMPH Phase 3 in progress.

Compound deep-dive

Tirzepatide: the dual GIP and GLP-1 receptor agonist

By the Lab77 Peptides team · 6 May 2026 · ~10 min read

A 39-amino-acid synthetic peptide developed by Eli Lilly that simultaneously activates both incretin receptors. The first twincretin to reach late-stage development. Beat semaglutide on every endpoint of SURPASS-2. Sits as the most-discussed compound in metabolic research right now, and the most actively counterfeited.

Compound deep-dive

BPC-157: the most-researched peptide in the catalogue

By the Lab77 Peptides team · 6 May 2026 · ~9 min read

A 15-amino-acid fragment derived from a body-protective compound first isolated from human gastric juice. Characterised at the University of Zagreb from 1991 onwards. Over 200 peer-reviewed papers. The unusual property that put it on the map: it survives gastric acid.

Compound deep-dive

Selank: the underrated Russian anxiolytic peptide

By the Lab77 Peptides team · 2 May 2026 · ~9 min read

A synthetic tuftsin analogue developed at the Russian Academy of Medical Sciences in the 1990s. Thirty years of literature on tuftsin-family receptor binding, GABAergic modulation, BDNF effects and the intranasal route - almost completely absent from Western research conversations.

Compound deep-dive

GHK-Cu explained: the blue copper peptide

By the Lab77 Peptides team · 1 May 2026 · ~8 min read

The copper-bound tripeptide first isolated by Pickart in 1973. Why it's vivid cobalt blue, what 50 years of literature says, how to verify a batch is real, and the supplier red flags almost no buyer knows to check.

Compound deep-dive

Semaglutide vs Retatrutide: single vs triple receptor agonist

Updated 26 April 2026 · ~6 min read

Side-by-side comparison of the two most-cited GLP-1-class compounds in current metabolic-research literature. Receptor pharmacology, half-life, lab handling.

Compound deep-dive

GHK-Cu vs BPC-157: copper tripeptide vs pentadecapeptide

Updated 26 April 2026 · ~5 min read

Two of the most widely cited regenerative-research peptides with very different chemistry. Mechanism, stability, selection criteria.

Compound deep-dive

CJC-1295 (DAC) vs Sermorelin: extended vs original GHRH

Updated 26 April 2026 · ~5 min read

Both are GHRH receptor agonists, but they differ dramatically in serum half-life. Why DAC modification changes everything.

Compound deep-dive

Semaglutide vs Tirzepatide vs Retatrutide: GLP-1 peptides compared (UK 2026)

By the Lab77 Peptides team · 30 September 2026 · ~10 min read

The four leading incretin-axis compounds side by side: receptor targets, half-life, Phase 2/3 weight-loss results, and how to choose between monoagonist, dual agonist, triple agonist, and amylin analogue depending on your research question.

Research guides

Research peptide stacks UK: the best combinations for 2026

By the Lab77 Peptides team · 30 September 2026 · ~9 min read

Six evidence-reviewed stacking frameworks used across UK research contexts: the Wolverine (BPC-157 + TB-500), GH-axis (CJC-1295 + Ipamorelin), skin-tissue (GHK-Cu + BPC-157), triple regenerative, longevity (NAD+ + Epithalon + MOTS-c), and nootropic (Selank + Semax). Quick-reference table with product page links.

UK regulation

UK legality of research peptides: the framework explained

Reference page · ~8 min read

The Misuse of Drugs Act 1971, MHRA marketing authorisation, and the research-reagent supply category. Plain-English explanation of where research peptides actually sit in UK law.